secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001104659-23-108353
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bankruptcy court confirms Mallinckrodt's prepackaged Chapter 11 plan; equity holders wiped out
--------------------------------------------------------------------------------

- Plan confirmed by Delaware bankruptcy court on Oct 10, 2023; emergence expected Q4 2023 after Irish examinership.
- First lien claims receive 92.3% of new common equity; second lien claims get 7.7%; existing equity holders receive nothing.
- New common equity will not be listed on any national securities exchange.
- Company had 13,371,707 ordinary shares outstanding as of Oct 9, 2023; all to be canceled on effective date.
- Consummation remains subject to Irish court approval of scheme of arrangement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465923108353/0001104659-23-108353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465923108353/tm2328021d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-108353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer